“If the FDA eventually grants an emergency authorization for either use, the government would make doses available at no cost and handle distribution.”
Meanwhile, Regeneron is working to meet its targeted goals as part of a $450 million contract that would divert up to 300,000 treatment courses to U.S. patients in the coming months.
Regeneron will provide bulk, unfinished lots of the cocktail as well as finished doses through 2020. If the FDA eventually grants an emergency authorization for either use, the government would make doses available at no cost and handle distribution.
The deal also includes the option to supply between 420,000 and 1.3 million preventive doses of REGN-COV2, which #Regeneron is currently pursuing in late-stage clinical trials.
No comments:
Post a Comment